Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies

J Hematol Oncol. 2022 Sep 12;15(1):132. doi: 10.1186/s13045-022-01320-5.

Abstract

Poor targeting of therapeutics leading to severe adverse effects on normal tissues is considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug delivery systems have provided an alternative avenue for improving the therapeutic potential of various agents and bioactive molecules through the enhanced permeability and retention (EPR) effect. Nanosystems with cancer-targeted ligands can achieve effective delivery to the tumor cells utilizing cell surface-specific receptors, the tumor vasculature and antigens with high accuracy and affinity. Additionally, stimuli-responsive nanoplatforms have also been considered as a promising and effective targeting strategy against tumors, as these nanoplatforms maintain their stealth feature under normal conditions, but upon homing in on cancerous lesions or their microenvironment, are responsive and release their cargoes. In this review, we comprehensively summarize the field of active targeting drug delivery systems and a number of stimuli-responsive release studies in the context of emerging nanoplatform development, and also discuss how this knowledge can contribute to further improvements in clinical practice.

Keywords: Active targeting; Cancer treatment; Drug delivery; Stimuli-responsive materials; Targeted strategies.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Delivery Systems
  • Humans
  • Ligands
  • Nanoparticles* / therapeutic use
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • Tumor Microenvironment

Substances

  • Ligands